Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 25:45:126633.
doi: 10.1016/j.vaccine.2024.126633. Epub 2025 Jan 3.

A framework for monitoring RSV prevention product effectiveness in the United States

Lauren E Roper  1 , Ruth Link-Gelles  2 , Diya Surie  2 , Jennifer DeCuir  2 , Laura D Zambrano  2 , Mila M Prill  2 , Fiona P Havers  2 , Jefferson M Jones  2 , Michael Melgar  2 , Aron J Hall  2 , Ralph D Whitehead Jr  2 , Meredith L McMorrow  2 , George N Ioannou  3 , Alfonso C Hernandez-Romieu  2 , Amadea Britton  2 , Shannon Novosad  4 , Abby Martin  2 , Leora R Feldstein  5 , Kristina L Bajema  6 , Hannah Kirking  2 , Heidi Moline  2 , Angela P Campbell  2 , Mihaela Aslan  7 , Kelly Hatfield  2 , Fatimah Dawood  2 , Rachel Slayton  4 , Sujan Reddy  4 , Danica Gomes  4 , Katherine E Fleming-Dutra  2 , Amanda B Payne  2
Affiliations

A framework for monitoring RSV prevention product effectiveness in the United States

Lauren E Roper et al. Vaccine. .

Abstract

During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV illness in infants and older adults. CDC, in collaboration with federal, public health, and academic partners, is conducting evaluations of real-world effectiveness of recommended RSV immunization products in the United States. Similar frameworks for evaluation are being applied to RSV vaccines and nirsevimab, a long-acting preventative monoclonal antibody, to estimate product effectiveness. The overall goal of CDC's RSV immunization effectiveness program is to generate timely and robust evidence through observational studies to inform immunization product policy decisions and other measures related to RSV prevention and control. CDC is evaluating effectiveness through high-quality, well-controlled observational studies leveraging a variety of platforms that provide robust data to inform policy decisions.

Keywords: Effectiveness; Immunization; Respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

MeSH terms

Substances

LinkOut - more resources